Phathom Pharmaceuticals commercializes treatments for acid-related gastrointestinal diseases, led by VOQUEZNA (vonoprazan), a potassium-competitive acid blocker (PCAB). The drug is approved in the U.S. for erosive and non-erosive GERD-related indications and, with antibiotics, for H. pylori infection; rights were licensed from Takeda for major Western markets. The company focuses on bringing this newer acid-suppression class to patients and physicians long reliant on traditional PPIs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 28.5 | — | -94.3 | — |
| Q2 2025 | 39.5 | — | -75.8 | — |
| Q3 2025 | 49.5 | — | -30 | — |
| Q4 2025 | 57.6 | — | -21.1 | — |
| Q1 2026 | 58.3 | 104.4% | -30.4 | — |
| Q2 2026 | 74.3 | 88% | -17.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Civista Bancshares, Inc. (CIVB), HIVE Digital Technologies Ltd. (HIVE), Bank7 Corp. (BSVN), Hallador Energy Company (HNRG), Ballard Power Systems Inc. (BLDP), American Bitcoin Corp (ABTC)